CA Nanotherapeutics

We are a small biotech company working on radically new ways of treating cancer. Our product aims at revolutionising the conventional anti-cancer therapy using nanoparticle carriers that will deliver the effective combinations of drugs directly to cancer cells. Our nanoparticles contain two or more anticancer drugs that are carefully designed to work in synergy.
Our product has shown excellent efficacy and virtually zero toxicity, superior to current gold-standard or newly emerging competitive technologies. Our project won the AstraZeneca-Skolkovo Start-up Challenge 2020.

The main entry advantage for our nanoparticle therapy is the increased efficacy, lack of systemic toxicity and overcoming chemoresistance demonstrated in our two studies. The additional advantage is a relatively low cost (£10k per patient).

We are currently looking for investors to complete the pre-clinical development (the required investment is 500 thousand euros). Clinical Phase I trial has already been pre-agreed with Kings College London.